Healthcare >> CEO Interviews >> October 1, 2001
PAUL E. FREIMAN joined Neurobiological Technologies, Inc., as a Director
in April 1997 and was elected President and Chief Executive Officer in
May 1997. He is the former Chairman and Chief Executive Officer of
Syntex Corporation, where he had a long and successful career and was
instrumental in the sale of Syntex to Roche Holdings for $5.3 billion.
He is credited with much of the marketing success of Syntex's lead
product, Naprosyn, and was responsible for moving the product to over-
the-counter status, marketed by Proctor & Gamble as Aleve. Mr. Freiman
currently serves as Chairman of the Board of SciGen Pte. Ltd., and
serves on the Boards of Penwest Pharmaceutical Co., Calypte Biomedical
Corporation, Alexza Molecular Delivery Corp., Phytos, Inc., and Otsuka
America Pharmaceuticals, Inc. He has been Chairman of the Pharmaceutical
Manufacturers Association of America (PhRMA) and has also chaired a
number of key PhRMA committees. Mr. Freiman holds a BS degree from
Fordham University and an Honorary Doctorate from the Arnold & Marie
Schwartz College of Pharmacy. Profile
Mr. Freiman: Neurobiological Technologies (NTI) was founded in 1987 by
some research scientists in San Francisco who focused
